Litigation Details for Allergan, Inc. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
✉ Email this page to a colleague
Allergan, Inc. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-08-10 |
| Court | District Court, D. Delaware | Date Terminated | 2019-01-02 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,248,191 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan, Inc. v. Saptalis Pharmaceuticals, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Allergan, Inc. v. Saptalis Pharmaceuticals, LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-08-10 | 1 | Complaint | United States Patent Nos. 8,633,162 (“the ’162 Patent”) and 8,642,556 (“the ’556 Patent”) (collectively… the ’556 Patent. B. Prior Litigation regarding patents related to the Patents-in-Suit …the two Patents-in-Suit along with four additional patents that cover RESTASIS®— U.S. Patent Nos. 8,629,111…,111 (“the ’111 Patent”), 8,648,048 (“the ’048 Patent”), 8,685,930 (“the ’930 Patent”), and 9,248,191…collectively, “the Patents-in-Suit”) under the Patent Laws of the United States, 35 U.S.C. § 1 et seq., relating | External link to document |
| 2018-08-10 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,633,162 ;8,642,556. (crb) (…2018 3 January 2019 1:18-cv-01231 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
